These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 30031743

  • 21. Real-Time 3-Dimensional Echocardiographic Assessment of Effective Regurgitant Orifice Area in Dogs With Myxomatous Mitral Valve Disease.
    Tidholm A, Bodegård-Westling A, Höglund K, Häggström J, Ljungvall I.
    J Vet Intern Med; 2017 Mar; 31(2):303-310. PubMed ID: 28109120
    [Abstract] [Full Text] [Related]

  • 22. Echocardiographic Estimates of Right Ventricular Systolic Function in Dogs with Myxomatous Mitral Valve Disease.
    Chapel EH, Scansen BA, Schober KE, Bonagura JD.
    J Vet Intern Med; 2018 Jan; 32(1):64-71. PubMed ID: 29224256
    [Abstract] [Full Text] [Related]

  • 23. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
    Boswood A, Gordon SG, Häggström J, Vanselow M, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P.
    J Vet Intern Med; 2020 May; 34(3):1108-1118. PubMed ID: 32200574
    [Abstract] [Full Text] [Related]

  • 24. Prognostic value of pulmonary vascular resistance estimated by echocardiography in dogs with myxomatous mitral valve disease and pulmonary hypertension.
    Yuchi Y, Suzuki R, Yasumura Y, Saito T, Teshima T, Matsumoto H, Koyama H.
    J Vet Intern Med; 2023 May; 37(3):856-865. PubMed ID: 36994902
    [Abstract] [Full Text] [Related]

  • 25. Two-dimensional echocardiographic estimates of left atrial function in healthy dogs and dogs with myxomatous mitral valve disease.
    Dickson D, Caivano D, Matos JN, Summerfield N, Rishniw M.
    J Vet Cardiol; 2017 Dec; 19(6):469-479. PubMed ID: 29111284
    [Abstract] [Full Text] [Related]

  • 26. Use of vertebral left atrial size for staging of dogs with myxomatous valve disease.
    Mikawa S, Nagakawa M, Ogi H, Akabane R, Koyama Y, Sakatani A, Ogawa M, Miyakawa H, Shigemoto J, Tokuriki T, Toda N, Miyagawa Y, Takemura N.
    J Vet Cardiol; 2020 Aug; 30():92-99. PubMed ID: 32707334
    [Abstract] [Full Text] [Related]

  • 27. Mitral valve morphology assessed by three-dimensional transthoracic echocardiography in healthy dogs and dogs with myxomatous mitral valve disease.
    Menciotti G, Borgarelli M, Aherne M, Wesselowski S, Häggström J, Ljungvall I, Lahmers SM, Abbott JA.
    J Vet Cardiol; 2017 Apr; 19(2):113-123. PubMed ID: 28279678
    [Abstract] [Full Text] [Related]

  • 28. Echocardiographic predictors of survival in dogs with myxomatous mitral valve disease.
    Sargent J, Muzzi R, Mukherjee R, Somarathne S, Schranz K, Stephenson H, Connolly D, Brodbelt D, Fuentes VL.
    J Vet Cardiol; 2015 Mar; 17(1):1-12. PubMed ID: 25586168
    [Abstract] [Full Text] [Related]

  • 29. Protective effects of omega-3 fatty acids in dogs with myxomatous mitral valve disease stages B2 and C.
    Nasciutti PR, Moraes AT, Santos TK, Gonçalves Queiroz KK, Costa APA, Amaral AR, Fernando Gomes Olivindo R, Pontieri CFF, Jeremias JT, Vendramini THA, Brunetto MA, Carvalho ROA.
    PLoS One; 2021 Mar; 16(7):e0254887. PubMed ID: 34265016
    [Abstract] [Full Text] [Related]

  • 30. Use of physical examination, electrocardiography, radiography, and biomarkers to predict echocardiographic stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels.
    Wesselowski S, Gordon SG, Fries R, Saunders AB, Sykes KT, Vitt J, Boutet B, Häggström J, Kadotani S, Stack J, Barnett BG.
    J Vet Cardiol; 2023 Dec; 50():1-16. PubMed ID: 37913604
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Åblad B, Bussadori CM, Glaus T, Kovačević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2013 Dec; 27(6):1441-51. PubMed ID: 24010489
    [Abstract] [Full Text] [Related]

  • 33. Prospective pilot study on the predictive significance of plasma miR-30b-5p through the study of echocardiographic modifications in Cavalier King Charles Spaniels affected by different stages of myxomatous mitral valve disease: The PRIME study.
    Ghilardi S, Lecchi C, Bagardi M, Romito G, Colombo FM, Polli M, Franco C, Brambilla PG.
    PLoS One; 2022 Dec; 17(12):e0274724. PubMed ID: 36574372
    [Abstract] [Full Text] [Related]

  • 34. Echocardiographic anatomy of the mitral valve in healthy dogs and dogs with myxomatous mitral valve disease.
    Wesselowski S, Borgarelli M, Menciotti G, Abbott J.
    J Vet Cardiol; 2015 Jun; 17(2):97-106. PubMed ID: 26003902
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Prediction of clinically important acquired cardiac disease without an echocardiogram in large breed dogs using a combination of clinical, radiographic and electrocardiographic variables.
    Wesselowski S, Gordon SG, Meddaugh N, Saunders AB, Häggström J, Cusack K, Janacek BW, Matthews DJ.
    J Vet Cardiol; 2022 Apr; 40():126-141. PubMed ID: 34483077
    [Abstract] [Full Text] [Related]

  • 37. Predictors of reoccurrence of congestive signs within 180 days after successful treatment of the first episode of congestive heart failure in dogs with myxomatous mitral valve disease.
    Franchini A, Abbott JA, Tyrrell W, Rosenthal S, Lahmers S, Menciotti G, Crosara S, Häggström J, Borgarelli M.
    J Vet Cardiol; 2021 Apr; 34():112-119. PubMed ID: 33706221
    [Abstract] [Full Text] [Related]

  • 38. Myxomatous mitral valve disease in Labrador Retrievers and Golden Retrievers.
    Wilson BA, Wesselowski S.
    J Am Vet Med Assoc; 2024 Nov 01; 262(11):1467-1475. PubMed ID: 38906175
    [Abstract] [Full Text] [Related]

  • 39. The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs.
    Vezzosi T, Grosso G, Tognetti R, Meucci V, Patata V, Marchesotti F, Domenech O.
    J Vet Intern Med; 2021 May 01; 35(3):1238-1244. PubMed ID: 33951235
    [Abstract] [Full Text] [Related]

  • 40. Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease.
    Li Q, Freeman LM, Rush JE, Laflamme DP.
    Int J Mol Sci; 2015 Jun 19; 16(6):14098-108. PubMed ID: 26101868
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.